Harvard Catalyst Profiles
Contact, publication, and social network information about Harvard faculty and fellows.
Open Source Software
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7.
Oncogenic BRAF and the tumor suppressor IGFBP7 in the genesis of atypical spitzoid nevomelanocytic proliferations.
Efficacy of IGFBP7 for treatment of metastatic melanoma and other cancers in mouse models and human cell lines.
Oncogenic BRAF-positive dysplastic nevi and the tumor suppressor IGFBP7--challenging the concept of dysplastic nevi as precursor lesions?
Role for IGFBP7 in senescence induction by BRAF.
Mixed versus pure variants of desmoplastic melanoma: a genetic and immunohistochemical appraisal.
Proto-Oncogene Proteins B-raf
Neurofibromin protein loss in desmoplastic melanoma subtypes: implicating NF1 allelic loss as a distinct genetic driver?
On oncogenic BRAF, melanomagenesis and organ transplant recipients--"the more we know, the less we understand".
Cutaneous adverse events to type I BRAF inhibitors: an analysis of effects associated with each inhibitor and therapeutic time interval to onset.
BRAF and Epithelial-Mesenchymal Transition: Lessons From Papillary Thyroid Carcinoma and Primary Cutaneous Melanoma.
Correlation of chemokine receptor CXCR4 mRNA in primary cutaneous melanoma with established histopathologic prognosticators and the BRAF status.
Mutation stability in primary and metastatic melanoma: what we know and what we don't.
Microvessel density, lymphovascular density, and lymphovascular invasion in primary cutaneous melanoma-correlation with histopathologic prognosticators and BRAF status.
BRAF and epithelial-mesenchymal transition in primary cutaneous melanoma: a role for Snail and E-cadherin?
The HGF-cMET signaling pathway in conferring stromal-induced BRAF-inhibitor resistance in melanoma.
Immunohistochemistry with a mutation-specific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma.
miR-146a promotes the initiation and progression of melanoma by activating Notch signaling.
Concordance of somatic mutation profiles (BRAF,NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples.
Proto Oncogene Proteins B raf